SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Åvall K)
 

Sökning: WFRF:(Åvall K) > (2020-2022) > Implementation of N...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008722naa a2200781 4500
001oai:gup.ub.gu.se/303895
003SwePub
008240528s2021 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:07269628-3884-4acf-902d-419d2fb04811
009oai:prod.swepub.kib.ki.se:146262202
009oai:DiVA.org:liu-175068
009oai:DiVA.org:uu-441961
0247 a https://gup.ub.gu.se/publication/3038952 URI
0247 a https://doi.org/10.1016/j.ygyno.2021.01.0122 DOI
0247 a https://lup.lub.lu.se/record/07269628-3884-4acf-902d-419d2fb048112 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1462622022 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1750682 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4419612 URI
040 a (SwePub)gud (SwePub)lud (SwePub)kid (SwePub)liud (SwePub)uu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Dahm-Kähler, Pernilla,d 1964u University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi,Institute of Clinical Sciences, Department of Obstetrics and Gynecology,Sahlgrenska University Hospital,Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Obstet & Gynecol, Sahlgrenska Acad, Gothenburg, Sweden.4 aut0 (Swepub:gu)xdahmp
2451 0a Implementation of National Guidelines increased survival in advanced ovarian cancer-A population-based nationwide SweGCG study
264 1b Elsevier BV,c 2021
500 a Funding Agencies|Swedish Cancer SocietySwedish Cancer Society [CAN 2017/594, 17 0333]; Cancer Society in Stockholm; SQRGC
520 a Aim. The first Swedish National Guidelines for Ovarian Cancer (NGOC) were published in 2012. We aimed to evaluate surgical outcomes and survival in patients with stage IIIC-IV disease, before and after the NGOC implementation. Method. Women with primary epithelial ovarian cancer, FIGO stage IIIC?IV, registered in the Swedish Quality Registry for Gynecologic Cancer 2008?2011 and 2013?2016 were included. Surgical outcomes were analyzed, including frequency of complete cytoreduction (R0). Relative survival (RS) and excess mortality rate ratios (EMRRs) were computed as measures of survival. Univariable and multivariable regression (Poisson) were calculated. Results. In total, 3728 women were identified, 1746 before and 1982 after NGOC. After adjusting for age and stage, survival was improved 2013?2016 vs. 2008?2011 (EMRR 0.89; 95%CI:0.82?0.96, p < 0.05). For women undergoing primary debulking surgery (PDS), R0 frequency (28.9% vs. 53.3%; p < 0.001) and 5-year RS (29.6% (95% CI:26.8?32.8) vs. 37.4% (95%CI:33.6?41.7)) were increased, but fewer patients (58% vs. 44%, p < 0.001) underwent PDS after NGOC implementation. Median survival for the PDS cohort increased from 35 months (95%CI,32.8?39.2) to 43 months (95%CI,40.9?46.4). In the neoadjuvant chemotherapy (NACT) + interval debulking surgery (IDS) cohort, R0 increased (36.8% to 50.1%, p < 0.001), but not 5-year RS (17.5% vs. 20.7%,ns). Compared to PDS, the EMRR was 1.32 (95%CI,1.19 & ndash;1.47, p < 0.001) for NACT+IDS and 3.00 (95% CI,2.66 & ndash;3.38, p < 0.001) for chemotherapy alone. In multivariable analyses, PDS, R0, age <= 70 years, and stage IIIC were found to be independent factors for improved RS. Conclusion. Implementation of the first National Guidelines for Ovarian Cancer improved relative survival in advanced ovarian cancer. (c) 2021 Published by Elsevier Inc.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reproduktionsmedicin och gynekologi0 (SwePub)302202 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Obstetrics, Gynaecology and Reproductive Medicine0 (SwePub)302202 hsv//eng
653 a Ovarian cancer
653 a Primary debulking surgery
653 a Radicality
653 a Neoadjuvant
653 a chemotherapy
653 a Interval debulking surgery
653 a Survival
653 a Centralization
653 a Guideline
653 a Oncology
653 a Obstetrics & Gynecology
653 a Neoadjuvant chemotherapy
653 a Ovarian cancer; Primary debulking surgery; Radicality; Neoadjuvant chemotherapy; Interval debulking surgery; Survival; Centralization; Guideline
7001 a Holmberg, Eriku Regional Cancer Center Western Sweden,Reg Canc Ctr Western Sweden, Gothenburg, Sweden.4 aut0 (Swepub:lu)jur-eho
7001 a Holtenman, M.u Regional Cancer Center Western Sweden,Reg Canc Ctr Western Sweden, Gothenburg, Sweden.4 aut
7001 a Radestad, A. F.u Karolinska Institutet,Karolinska Institute,Karolinska Inst, Dept Womens & Childrens Hlth, Div Obstet & Gynecol, Stockholm, Sweden.4 aut
7001 a Borgfeldt, Christeru Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Gynekologisk cancer, förebyggande av cancer och osteoporos,Forskargrupper vid Lunds universitet,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Gynecological Cancer and Cancer prevention as well as prevention of Osteoporosis,Lund University Research Groups,Skåne University Hospital,Lund Univ, Skane Univ Hosp, Dept Obstet & Gynecol, Dept Clin Sci, Lund, Sweden.4 aut0 (Swepub:lu)gyn-cbo
7001 a Hjerpe, E.u Visby hospital,Visby Hosp, Dept Obstet & Gynecol, Visby, Sweden.4 aut
7001 a Marcickiewicz, J.u Hallands sjukhus, Varberg,Varbergs Hosp, Dept Obstet & Gynecol, Region Halland, Sweden.4 aut
7001 a Bjurberg, Mariau Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröst/ovarialcancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast/ovarian cancer,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Skane Univ Hosp, Dept Hematol, Radiat Phys,Oncol, Lund, Sweden.4 aut0 (Swepub:lu)onk-mbj
7001 a Tholander, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)betho227
7001 a Hellman, K.u Karolinska University Hospital,Karolinska Univ Hosp, Dept Gynecol Canc, Theme Canc, Stockholm, Sweden.4 aut
7001 a Kjölhede, Prebenu Linköpings universitet,Linköping University,Avdelningen för barns och kvinnors hälsa,Medicinska fakulteten,Region Östergötland, Kvinnokliniken US,Linköping Univ, Dept Obstet & Gynecol, Dept Biomed & Clin Sci, Linköping, Sweden.4 aut0 (Swepub:liu)prekj14
7001 a Högberg, Thomasu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Dept Canc Epidemiol, Dept Clin Sci, Lund, Sweden.4 aut0 (Swepub:lu)med-toh
7001 a Rosenberg, Peru Linköpings universitet,Linköping University,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Linköping Univ, Dept Oncol, Dept Biomed & Clin Sci, Linköping, Sweden.4 aut0 (Swepub:liu)perro95
7001 a Åvall Lundqvist, Elisabethu Linköpings universitet,Linköping University,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Linköping Univ, Dept Oncol, Dept Biomed & Clin Sci, Linköping, Sweden.4 aut0 (Swepub:liu)eliav51
7001 a Stålberg, Karinu Uppsala universitet,Uppsala University,Uppsala Univ, Sweden,Reproduktiv hälsa4 aut0 (Swepub:uu)kariglim
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi4 org
7730 t Gynecologic Oncologyd : Elsevier BVg 161:1, s. 244-250q 161:1<244-250x 0090-8258x 1095-6859
8564 u http://dx.doi.org/10.1016/j.ygyno.2021.01.012y FULLTEXT
8564 8u https://gup.ub.gu.se/publication/303895
8564 8u https://doi.org/10.1016/j.ygyno.2021.01.012
8564 8u https://lup.lub.lu.se/record/07269628-3884-4acf-902d-419d2fb04811
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:146262202
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-175068
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-441961

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy